FDA Approves Shockwave Coronary Intravascular Lithotripsy System
Executive Summary
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.
You may also be interested in...
Shockwave Begins First All-Female Study Of Coronary Interventions
The EMPOWER CAD trial will evaluate Shockwave’s intravascular lithotripsy system in female patients undergoing a percutaneous coronary intervention for coronary artery disease. Principal investigator Alexandra Lansky spoke to Medtech Insight about the first-of-its kind study in this understudied population.
Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.
Cardiovascular Catch-Up: Philips New AI Finds AF Needle In ECG Haystack; LimFlow Moves Closer To US Approval
Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small. Part two of this month's installment includes updates from lesser-known companies that you might have missed, including Cardiologs, Rhythm Management, LimFlow and ShockWave.